Untangling the interplay of genetic and metabolic influences on beta-cell function: Examples of potential therapeutic implications involving TCF7L2 and FFAR1

Molecular Metabolism

Volumn 3, Issue 3, 2014, Pages 261-267

  Wagner, Robert ^a,c   Staiger, Harald ^a,b,c   Ullrich, Susanne ^a,b,c   Stefan, Norbert ^a,b,c   Fritsche, Andreas ^a,b,c   Häring, Hans Ulrich ^a,b,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

Beta cell failure; Beta cell function; FFAR1; Gene environment interaction; Incretin resistance; Pharmacogenetics; TCF7L2

Indexed keywords

G PROTEIN COUPLED RECEPTOR 40; INCRETIN; INSULIN; TRANSCRIPTION FACTOR 7 LIKE 2;

CELL FUNCTION; DRUG MECHANISM; FATTY ACID METABOLISM; FFAR1 GENE; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PHARMACOGENETICS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TCF7L2 GENE;

EID: 84897108150     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2014.01.001     Document Type: Review

References (69)

1. Tuomi T., Santoro N., Caprio S., et al. The many faces of diabetes: a disease with increasing heterogeneity. The Lancet (13), 2013, 62219-9. http://dx.doi.org/10.1016/S0140-6736(13)62219-9.
2. Arterburn D.E., Bogart A., Sherwood N.E., et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obesity Surgery 2013, 23:93-102. 10.1007/s11695-012-0802-1.
3. Prentki M., Matschinsky F.M., Madiraju S.R.M. Metabolic signaling in fuel-induced insulin secretion. Cell Metabolism 2013, 18:162-185. 10.1016/j.cmet.2013.05.018.
4. Meier J.J., Nauck M.A. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?. Diabetes 2010, 59:1117-1125. 10.2337/db09-1899.
5. Henquin J.-C. The dual control of insulin secretion by glucose involves triggering and amplifying pathways in β-cells. Diabetes Research and Clinical Practice 2011, 93(uppl. 1):S27-S31. 10.1016/S0168-8227(11)70010-9.
6. Nolan C.J., Prentki M. The islet beta-cell: fuel responsive and vulnerable. Trends in Endocrinology & Metabolism 2008, 19:285-291. 10.1016/j.tem.2008.07.006.
7. Itoh Y., Kawamata Y., Harada M., et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003, 422:173-176. 10.1038/nature01478.
8. Ferdaoussi M., Bergeron V., Zarrouki B., et al. G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 2012, 55:2682-2692. 10.1007/s00125-012-2650-x.
9. Stefan N., Stumvoll M., Bogardus C., Tataranni P.A. Elevated plasma nonesterified fatty acids are associated with deterioration of acute insulin response in IGT but not NGT. American Journal of Physiology - Endocrinology and Metabolism 2003, 284:E1156-E1161. 10.1152/ajpendo.00427.2002.
10. Stefan N., Wahl H.G., Fritsche A., et al. Effect of the pattern of elevated free fatty acids on insulin sensitivity and insulin secretion in healthy humans. Hormone and Metabolic Research 2001, 33:432-438. 10.1055/s-2001-16231.
11. Kashyap S., Belfort R., Gastaldelli A., et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop Type 2 diabetes. Diabetes 2003, 52:2461-2474. 10.2337/diabetes.52.10.2461.
12. Mandrup-Poulsen T. Beta-cell apoptosis: stimuli and signaling. Diabetes 2001, 50:S58. 10.2337/diabetes.50.2007.S58.
13. Eitel K., Staiger H., Rieger J., et al. Protein kinase C δ activation and translocation to the nucleus are required for fatty acid-induced apoptosis of insulin-secreting cells. Diabetes 2003, 52:991-997. 10.2337/diabetes.52.4.991.
14. Hennige A.M., Ranta F., Heinzelmann I., et al. Overexpression of kinase-negative protein kinase Cdelta in pancreatic beta-cells protects mice from diet-induced glucose intolerance and beta-cell dysfunction. Diabetes 2010, 59:119-127. 10.2337/db09-0512.
15. Poitout V., Robertson R.P. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocrine Reviews 2008, 29:351-366. 10.1210/er.2007-0023.
16. Almgren P., Lehtovirta M., Isomaa B., et al. Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study. Diabetologia 2011, 54:2811-2819. 10.1007/s00125-011-2267-5.
17. Staiger H., Machicao F., Fritsche A. Pathomechanisms of type 2 diabetes genes. Endocrine Reviews 2009, 30:557-585. Haring H-U.
18. Wagner R., Dudziak K., Herzberg-Schäfer S.A., et al. Glucose-raising genetic variants in MADD and ADCY5 impair conversion of proinsulin to insulin. PLoS ONE 2011, 6:e23639. 10.1371/journal.pone.0023639.
19. Dimas A.S., Lagou V., Barker A., et al. Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 2013, 10.2337/db13-0949.
20. Kirchhoff K., Machicao F., Haupt A., et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia 2008, 51:597-601.
21. Schulze M.B., Weikert C., Pischon T., et al. Use of multiple metabolic and genetic markers to improve the prediction of type 2 diabetes: the EPIC-Potsdam Study. Diabetes Care 2009, 32:2116-2119. 10.2337/dc09-0197.
22. Zeggini E., Scott L.J., Saxena R., et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature Genetics 2008, 40:638-645. 10.1038/ng.120.
23. Grant S.F.A., Thorleifsson G., Reynisdottir I., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nature Genetics 2006, 38:320-323. 10.1038/ng1732.
24. Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 2007, 447:661-678. Wellcome Trust Case Control Consortium. 10.1038/nature05911.
25. Saxena R., Gianniny L., Burtt N.P., et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006, 55:2890-2895. 10.2337/db06-0381.
26. Florez J.C., Jablonski K.A., Bayley N., et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. New England Journal of Medicine 2006, 355:241-250. 10.1056/NEJMoa062418.
27. Fritsche A., Stefan N., Hardt E., et al. A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility. European Journal of Clinical Investigation 2000, 30:411-418.
28. Schäfer S.A., Tschritter O., Machicao F., et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007, 50:2443-2450. 10.1007/s00125-007-0753-6.
29. Lyssenko V., Lupi R., Marchetti P., et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. Journal of Clinical Investigation 2007, 117:2155-2163. 10.1172/JCI30706.
30. Pilgaard K., Jensen C.B., Schou J.H., et al. The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 2009, 52:1298-1307. 10.1007/s00125-009-1307-x.
31. Villareal D.T., Robertson H., Bell G.I., et al. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010, 59:479-485. 10.2337/db09-1169.
32. Smushkin G., Sathananthan M., Sathananthan A., et al. Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1. Diabetes 2012, 61:1082-1089. 10.2337/db11-1732.
33. Kjems L.L., Holst J.J., Vølund A., Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52:380-386.
34. Heni M., Ketterer C., Thamer C., et al. Glycemia determines the effect of type 2 diabetes risk genes on insulin secretion. Diabetes 2010, 59:3247-3252. 10.2337/db10-0674.
35. Müssig K., Staiger H., Machicao F., et al. Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia 2010, 53:2289-2297.
36. Campbell J.E., Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism 2013, 17:819-837. 10.1016/j.cmet.2013.04.008.
37. Ordelheide A.-M., Gerst F., Rothfuss O., et al. Nor-1, a novel incretin-responsive regulator of insulin genes and insulin secretion. Molecular Metabolism 2013, 2:243-255. 10.1016/j.molmet.2013.06.003.
38. Da Silva Xavier G., Loder M.K., McDonald A., et al. TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells. Diabetes 2009, 58:894-905. 10.2337/db08-1187.
39. Shu L., Zien K., Gutjahr G., et al. TCF7L2 promotes beta cell regeneration in human and mouse pancreas. Diabetologia 2012, 55:3296-3307.
40. Takamoto I., Kubota N., Nakaya K., et al. TCF7L2 in mouse pancreatic beta cells plays a crucial role in glucose homeostasis by regulating beta cell mass. Diabetologia, 2013, 1-12. http://dx.doi.org/10.1007/s00125-013-3131-6.
41. Boj S.F., van Es J.H., Huch M., et al. Diabetes risk gene and wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell 2012, 151:1595-1607. 10.1016/j.cell.2012.10.053.
42. Prokunina-Olsson L., Welch C., Hansson O., et al. Tissue-specific alternative splicing of TCF7L2. Human Molecular Genetics 2009, 18:3795-3804. 10.1093/hmg/ddp321.
43. Kaminska D., Kuulasmaa T., Venesmaa S., et al. Adipose tissue TCF7L2 splicing is regulated by weight loss and associates with glucose and fatty acid metabolism. Diabetes 2012, 61:2807-2813. 10.2337/db12-0239.
44. Schäfer S.A., Müssig K., Staiger H., et al. A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion. Diabetologia 2009, 52:1075-1082. 10.1007/s00125-009-1344-5.
45. 't Hart L.M., Fritsche A., Nijpels G., et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes 2013, 62:3275-3281. 10.2337/db13-0227.
46. Fisher E., Boeing H., Fritsche A., et al. Whole-grain consumption and transcription factor-7-like 2 ( TCF7L2) rs7903146: gene-diet interaction in modulating type 2 diabetes risk. British Journal of Nutrition 2009, 101:478-481. 10.1017/S0007114508020369.
47. Cornelis M.C., Qi L., Kraft P., Hu F.B. TCF7L2, dietary carbohydrate, and risk of type 2 diabetes in US women. American Journal of Clinical Nutrition 2009, 89:1256-1262. 10.3945/ajcn.2008.27058.
48. Hindy G., Sonestedt E., Ericson U., et al. Role of TCF7L2 risk variant and dietary fibre intake on incident type 2 diabetes. Diabetologia 2012, 55:2646-2654. 10.1007/s00125-012-2634-x.
49. Haupt A., Thamer C., Heni M., et al. Gene variants of TCF7L2 influence weight loss and body composition during lifestyle intervention in a population at risk for type 2. Diabetes 2010, 59:747-750. 10.2337/db09-1050.
50. Heni M., Herzberg-Schafer S., Machicao F., et al. Dietary fiber intake modulates the association between variants in TCF7L2 and weight loss during a lifestyle intervention. Diabetes Care 2012, 35:e24. 10.2337/dc11-2012.
51. Corella D., Carrasco P., Sorlí J.V., et al. Mediterranean diet reduces the adverse effect of the TCF7L2-rs7903146 polymorphism on cardiovascular risk factors and stroke incidence a randomized controlled trial in a high-cardiovascular-risk population. Dia Care DC_130955 2013, 10.2337/dc13-0955.
52. Karnes J.H., Gong Y., Pacanowski M.A., et al. Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenetics and Genomics 2013, 23:697-705. 10.1097/FPC.0000000000000012.
53. Pearson E.R., Donnelly L.A., Kimber C., et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007, 56:2178-2182. 10.2337/db07-0440.
54. Holstein A., Hahn M., Körner A., et al. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Medical Genetics 2011, 12:30.
55. Javorský M., Babjaková E., Klimčáková L., et al. Association between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazide. International Journal of Endocrinology 2013, 2013:374858. 10.1155/2013/374858.
56. Zhang C.-L., Katoh M., Shibasaki T., et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science Signaling 2009, 325:607.
57. Herzberg-Schäfer S., Heni M., Stefan N., et al. Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia. Diabetes, Obesity and Metabolism 2012, 14:85-90. 10.1111/j.1463-1326.2012.01648.x.
58. Del Guerra S., Bugliani M., D'Aleo V., et al. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. Nutrition, Metabolism and Cardiovascular Diseases 2010, 20:22-25. 10.1016/j.numecd.2009.02.008.
59. Lan H., Hoos L.M., Liu L., et al. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 2008, 57:2999-3006. 10.2337/db08-0596.
60. Wu P., Yang L., Shen X. The relationship between GPR40 and lipotoxicity of the pancreatic β-cells as well as the effect of pioglitazone. Biochemical and Biophysical Research Communications 2010, 403:36-39. 10.1016/j.bbrc.2010.10.105.
61. Wagner R., Kaiser G., Gerst F., et al. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes 2013, 62:2106-2111. 10.2337/db12-1249.
62. Vettor R., Granzotto M., Stefani D.D., et al. Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. Journal of Clinical Endocrinology and Metabolism 2008, 93:3541-3550. 10.1210/jc.2007-2680.
63. Poitout V., Lin DC-H Modulating GPR40: therapeutic promise and potential in diabetes. Drug Discovery Today 2013, 18:1301-1308. 10.1016/j.drudis.2013.09.003.
64. Franks P.W. Gene×environment interactions in type 2 diabetes. Current Diabetes Reports 2011, 11:552-561. 10.1007/s11892-011-0224-9.
65. Aschard H., Chen J., Cornelis M.C., et al. Inclusion of gene-gene and gene-environment interactions unlikely to dramatically improve risk prediction for complex diseases. American Journal of Human Genetics 2012, 90:962-972. 10.1016/j.ajhg.2012.04.017.
66. Zheng J.-S., Arnett D.K., Lee Y.-C., et al. Genome-wide contribution of genotype by environment interaction to variation of diabetes-related traits. PLoS ONE 2013, 8:e77442. 10.1371/journal.pone.0077442.
67. Thomas D. Gene-environment-wide association studies: emerging approaches. Nature Reviews Genetics 2010, 11:259-272. 10.1038/nrg2764.
68. Patel C.J., Chen R., Kodama K., et al. Systematic identification of interaction effects between genome- and environment-wide associations in type 2 diabetes mellitus. Human Genetics 2013, 132:495-508. 10.1007/s00439-012-1258-z.
69. Franks P.W., Christophi C.A., Jablonski K.A., et al. Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program. Diabetologia, 2013, 1-6. http://dx.doi.org/10.1007/s00125-013-3133-4.